Elevation Oncology (NASDAQ:ELEV) Given “Market Perform” Rating at William Blair
William Blair reissued their market perform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report report published on Monday,Benzinga reports. Other analysts have also issued research reports about the company. Leerink Partners lowered Elevation Oncology from an “outperform” rating to a “market perform” rating and cut their price objective for […]
William Blair reissued their market perform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report report published on Monday,Benzinga reports. Other analysts have also issued research reports about the company. Leerink Partners lowered Elevation Oncology from an “outperform” rating to a “market perform” rating and cut their price objective for […]
